Tarrytown-based Regeneron is making a $100 million payment and equity investment in a collaboration with Mammoth Biosciences, Inc., of Brisbane, California. Mammoth is involved in genetic editing.
Regeneron said that its personnel will work with Mammoth’s personnel in efforts to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.
“We believe in the incredible power of gene editing, which we are utilizing in our diverse preclinical and clinical genetic medicines pipeline. After years spent developing our next-generation delivery approaches, we are eager to combine them with Mammoth’s gene editing systems to better match payload, delivery system and disease type,” said Christos Kyratsous, senior vice president and co-Head of Regeneron Genetic Medicines. “Together, we have the potential to overcome significant delivery hurdles and effectively reach tissues around the body, impact multiple diseases and dramatically increase the number of patients who could benefit from gene editing treatments.”
Under the terms of the agreement, Mammoth will receive $100 million that includes a $95 million equity investment at signing. Mammoth also could receive up to $370 million per target in development along with payments when regulatory and commercial milestones are met. In addition, there could be royalties on product sales.
“We believe we can further our mission to transform the lives of patients by accelerating the discovery and development of genetic medicines in collaboration with Regeneron,” Mammoth’s co-founder and CEO Trevor Martin said.
